

Institutional Review Board - Federalwide Assurance #00002988

Cincinnati Childrens Hospital Medical Center

Date: 1/4/2017
From: CCHMC IRB
To: Principal Investigator: Lawrence Dolan
Endocrinology
Re: Study ID: [2011-0407](#)
Study Title: SEARCH for Diabetes in Youth

The above referenced protocol and all applicable additional documentation provided to the IRB were reviewed and **RE-APPROVED** using an **EXPEDITED** review procedure set forth in 45 CFR 46.110(b)(1), Category(ies)(see below) on 1/4/2017.

For research involving children, the Committee determined that this research presents:

- No greater than minimal risk.

Please note the following requirements:

Consent Requirements

Per 45 CFR 46.116 (21 CFR 50.20) the IRB has determined that informed consent must be obtained from all adult participants and that this consent must be documented by signature on the IRB approval consent form.

Parental Permission Requirements

Per 45 CFR 46.408 the IRB has determined that at least 1 parent (or guardian) must give permission for the inclusion of a child in this research and that permission must be documented by signature on the IRB approved parental permission form.

Assent Requirements

Per 45 CFR 46.408 the IRB has determined that documented assent must also be obtained from all child participants 11 years of age and above unless otherwise specified in the protocol and/or smart form.

HIPAA Requirements

Per 45 CFR 164.508 the IRB has determined that all adult participants and/or the legally authorized representative of child participants must provide authorization for the use and/or disclosure of the protected health information in the conduct of this research.

This study will be due for continuing review at least 30 days before 1/3/2018.

Study Documents

2014 Fall Newsletter

Atrium approval - expires 9/20/17

BCMh (OH Dept. of Health) approval - expires 11/12/16

Birthday card

Brief contact update

Brochure - follow-up

Certificate of appreciation

Certificate of appreciation

Certificate of Confidentiality

CES-D

CES-D - Spanish

Chort >18 no echo

Christ approval - expires 1/1/17

Clincard receipt - adult

Clincard receipt - under 18 yrs

Clincard tips

Cohort <18 no echo

Cohort <18 with echo

Cohort >18 with echo

Cohort description - questionnaires only - adult

Cohort description - questionnaires only - under 18

Cohort description 5-10 years

Cohort description adult

Cohort description under 18

Cohort description with Echo - adult

Cohort description with Echo - under 18

Cohort instructions

Cohort instructions - Spanish

Cohort intro letter

Cohort reminder letter

Cohort reminder letter - Spanish

Consent for 2012 visits - Spanish - short form

Consent for 2016 visits adult

Consent for 2016 visits parent

Consent for single follow up visit - Spanish - short form

Consent for single follow-up visits adult
Consent for single follow-up visits parent
Consent for surveys only adult
Consent for surveys only parent
Consent for volunteers
Contact information - adult
Contact information - parent
Contact information - Spanish
Contact update - electronic
Contact update - survey only - adult
Contact update - survey only - parent
DVD cover
DVD disk label
Eating Problems
Eating problems - Spanish
Employment and Economics
Employment and Economics - Spanish
Eye Vision
Facebook page
Family conflict
Family conflict - Spanish
Family medical history
Food Frequency
Food frequency - Spanish
Food Insecurities and Assistance
Food Insecurities and Assistance - Spanish
Forms only letter - parent
Forms only letter over 18
Fort Hamilton Hughes waiver approval - no expiration
Health Care Usage Form
Health Questionnaire
Health Questionnaire - Spanish
Initial email - survey - adult
Initial email - survey - parent
Instruction email - survey - adult
Instruction email - survey - parent

Instruction letter - survey only - adult
Instruction letter - survey only - parent
Intro letter - survey only - adult
Intro letter - survey only - parent
IPS - adult
IPS - parent
IPS - Spanish
IPS letter - adult
IPS letter - Spanish
IPS letter - under 18
IPS thank you and IPV invitation - adult
IPS thank you and IPV invitation - under 18
IPS thank you letter
IPS thank you letter - outside cases
IPS thank you letter - outside cases and IPV invitation
IPS thank you letter - Spanish
IPS voucher
IPS Voucher - Spanish
January flyer - over 18 yrs.
January flyer - under 18
Lab results description - cohort
Lab results description - Spanish
Letter - eligible but unable to reach by phone
Letter - recruitment, registry visit
Letter - recruitment, registry visit - Spanish
Letter for 1st AM urine re-collection
Letter for both urine re-collection
Link to recruitment video
Link to study-wide public website
Continuing Review Documents:
Last consent.pdf
DSMB Reports
June 22.2016 - summary.docx
OSMB report 1.12.16.pdf
SEARCH Final Responses to OSMB Comments from Jan 2016.pdf

AMENDMENTS: The principal investigator is responsible for notifying the IRB of any changes in the protocol, participating investigators, procedures, recruitment, consent forms, FDA status, or conflicts of interest. Approval is based on the information as submitted. New procedures cannot be initiated until IRB approval has been given. If you wish to change any aspect of this study, please submit an Amendment via ePAS to the IRB, providing a justification for each requested change.

CONTINUING REVIEW: The investigator is responsible for submitting a Continuing Review via ePAS to the IRB at least 30 days prior to the expiration date listed above. Please note that study procedures may only continue into the next cycle if the IRB has reviewed and granted re-approval prior to the expiration date.

UNANTICIPATED PROBLEMS: The investigator is responsible for reporting unanticipated problems promptly to the IRB via ePAS according to current reporting policies.

STUDY COMPLETION: The investigator is responsible for notifying the IRB by submitting a Request to Close via ePAS when the research, including data analysis, has completed.

Research Categories

2. Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows: (a) from healthy, nonpregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an 8 week period and collection may not occur more frequently than 2 times per week; or (b) from other adults and children (2), considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may not occur more frequently than 2 times per week.

3. Prospective collection of biological specimens for research purposes by noninvasive means. Examples: (a) hair and nail clippings in a nondisfiguring manner; (b) deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction; (c) permanent teeth if routine patient care indicates a need for extraction; (d) excreta and external secretions (including sweat); (e) uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gumbase or wax or by applying a dilute citric solution to the tongue; (f) placenta removed at delivery; (g) amniotic fluid obtained at the time of rupture of the membrane prior to or during labor; (h) supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques; (i) mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings; (j) sputum collected after saline mist nebulization.

4. Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.) Examples: (a) physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject's privacy; (b) weighing or testing sensory acuity; (c) magnetic resonance imaging; (d) electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, doppler blood flow, and echocardiography; (e) moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual.

5. Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for nonresearch purposes (such as medical treatment or diagnosis). (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101 (b)(4). This listing refers only to research that is not exempt.)

7. Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies. (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b)(2) and (b)(3). This listing refers only to research that is not exempt.)

Please note: This approval is through the IRB only. You may be responsible for reporting to other regulatory officials (e.g. VA Research and Development Office, UC Health - University Hospital). Please check with your institution and department to ensure you have met all reporting requirements.

Statement regarding International conference on Harmonization and Good Clinical Practices: The Institutional Review Board is duly constituted (fulfilling FDA requirements for diversity), has written procedures for initial and continuing review of clinical trials; prepares written minutes of convened meetings, and retains records pertaining to the review and approval process; all in compliance with requirements defined in 21 CFR Parts 50, 56 and 312 Code of Federal Regulations. This institution is in compliance with the ICH GCP as adopted by FDA/DHHS.

Thank you for your cooperation during the review process.



To: Elizabeth Mayer-Davis
Nutrition Operations

From: Non-Biomedical IRB

Approval Date: 2/08/2017

Expiration Date of Approval: 2/07/2018

RE: Notice of IRB Approval by Expedited Review (under 45 CFR 46.110)

Submission Type: Renewal

Expedited Category:

Study #: 10-2341

Study Title: SEARCH for Diabetes in Youth: Carolina Site (SEARCH 4)

This submission has been approved by the IRB for the period indicated.

Study Description:

SEARCH for Diabetes in Youth is an observational multi-center study that has had ongoing data collection since 2002. This current application delineates work to be completed in SEARCH, Phase 4 (the 4th five year funding cycle) at the Carolina Site. SEARCH.

First, in the Registry Study, SEARCH will:

- Ascertain newly diagnosed in 2013 and forward incident cases of youth less than 20 years and living in SC at diagnosis;
- Provide consultation and support to inform development of low-cost sustainable public health surveillance system;
- Assess mortality among 2002-2015 incident cases (cases previously identified in SEARCH, Phases 1-3)

Secondly, in the Cohort Study, SEARCH will:

- Assess the prevalence and incidence of and risk factors for acute and chronic microvascular and macrovascular complications of diabetes;
- Determine the degree to which barriers of care, quality of care, and the process of transition from pediatric to adult care impact disease factors and diabetes-related outcomes;
- Maintain and supplement the previously established SEARCH repository for biological specimens

Thirdly, SEARCH will work with the TraCS Institute and a third-party machine-learning company, CoVar, to build one or more machine-learning algorithms that allow SEARCH investigators to extract date of diabetes diagnosis from the full-text clinical notes of (1) patients previously identified in SEARCH, Phase 3 and (2) patients to be identified in the current phase of SEARCH.

Submission Description:

1. Cohort study: the online survey packet and the paper forms packet have both been updated to reflect some edits and clarifications. A summary table of the edits has been added as a separate attachment. Previous versions of the cohort survey packets have been replaced with the updated version.

2. Cohort study: the invitation letter has been updated to include information that someone currently pregnant must wait to schedule visit until four months after pregnancy has ended. (This is not a change in protocol, but was not previously stated in the letter. We are adding to the letter to let participants who may be pregnant know that they need to wait to schedule (or reschedule a previously scheduled) visit.) The visit instructions were also edited to note this information about pregnancy and that if the participant was hospitalized for DKA within 4 weeks of their visit, they should call to reschedule.

3. Registry study: The visit instruction page was edited to note if the participant was hospitalized with DKA within 4 weeks of their visit, they should call to reschedule.

These documents will also be submitted to the Greenville Health System IRB for approval for the SC sites. They will not be implemented until approved by both IRBs.

Regulatory and other findings:

This research, which involves children, meets criteria at 45 CFR 46.404 and/or 21 CFR 50.51 (research involving no greater than minimal risk). Permission of one parent or guardian is sufficient. The surveys do not ask sensitive information and the blood draw and eye photography present minimal risk.

This research meets criteria for a waiver of written (signed) consent according to 45 CFR 46.117(c)(2) for: (1) completion of the IPS survey; (2) for the sample of cohort participants will complete survey-only data collection; and (3) for the collection of the overnight urine sample. Written consent will be collected before the urine is given to the research staff the next day.

This research meets criteria for waiver of informed consent for research [45 CFR 46.116(d)] and waiver of HIPAA authorization [45 CFR 164.512(i)(2)(ii)] for the case ascertainment and validation portion of the study.

This approval includes a limited waiver of HIPAA authorization to identify potential subjects for recruitment into this research study (**Registry Study only**), as allowed under 45 CFR 164.512. This temporary waiver provides access to protected health information (PHI) to confirm eligibility and facilitate initial contact, after which consent and HIPAA authorization will be sought. Access and use is limited to the minimum amount of PHI necessary to review eligibility criteria and to contact potential subjects.

Human subject interaction/intervention or interaction with identifiable data for SEARCH 4 may not occur until an updated Certificate of Confidentiality is uploaded through a modification.

The Board agreed that this research involves no more than minimal risk and future reviews may be done on an expedited basis, under Expedited Review, Category 9.

Social security numbers (SSN) may be collected for this study for tax identification and/or payment purposes. The subject is required to disclose his/her SSN in order to receive the incentive payment(s).

Investigator's Responsibilities:

Federal regulations require that all research be reviewed at least annually. It is the Principal Investigator's responsibility to submit for renewal and obtain approval before the expiration date. You may not continue any research activity beyond the expiration date without IRB approval. Failure to receive approval for continuation before the expiration date will result in automatic termination of the approval for this study on the expiration date.

If applicable, your approved consent forms and other documents are available online at http://apps.research.unc.edu/irb/index.cfm?event=home.dashboard.irbStudyManagement&irb_id=10-2341.

You are required to obtain IRB approval for any changes to any aspect of this study before they can be implemented. Any unanticipated problem involving risks to subjects or others (including adverse

events reportable under UNC-Chapel Hill policy) should be reported to the IRB using the web portal at <http://irbis.unc.edu>.

The current data security level determination is Level III. Any changes in the data security level need to be discussed with the relevant IT official. If data security level II and III, consult with your IT official to develop a data security plan. Data security is ultimately the responsibility of the Principal Investigator.

This study was reviewed in accordance with federal regulations governing human subjects research, including those found at 45 CFR 46 (Common Rule), 45 CFR 164 (HIPAA), 21 CFR 50 & 56 (FDA), and 40CFR 26 (EPA), where applicable.

CC:

Jennifer Law, Epidemiology Operations

Amy Mottl, Department of Medicine

Emily Pfaff, The North Carolina Translational and Clinical Sciences (TraCS) Institute

Joan Thomas, Nutrition Operations

Katherine Westreich, Medicine-Nephrology



GREENVILLE HEALTH SYSTEM

February 27, 2017

Bryce A. Nelson, MD, PhD
Attn: Joan Thomas
Children's Hospital
200 Patewood Drive
Greenville, SC 29605

RE: IRB File # Pro00010812

***Study Title:* SEARCH For Diabetes in Youth – Carolina Center, Phase 4**

***Items Submitted for IRB Review:* Protocol and Consent Form Continuing Review**

Dear Dr. Nelson:

On February 22, 2017, the Institutional Review Board/Committee-B (IRB) of the Greenville Health System reviewed your research study. Full committee approval of the above-mentioned items was given for one year.

Your study will **expire on February 21, 2018. It is the investigator's responsibility to make sure the proper reapproval information is submitted to the IRB.** This information must be submitted to the IRB in **January 2018.**

The same requirements as previously outlined for you by the IRB remain in effect as long as the study is ongoing. Please refer to your initial approval letter for these requirements.

Thank you for your assistance in this matter. If you have any questions, please feel free to call the IRB Office at (864) 455-4360.

Sincerely,

Robert A. Saul, MD, Chairman
Institutional Review Board/Committee-B
701 Grove Road, ESC Bldg.
Greenville, SC 29605

RAS/gh



Colorado Multiple Institutional Review Board, CB
F490
University of Colorado, Anschutz Medical Campus
13001 E. 17th Place, Building 500, Room N3214
Aurora, Colorado 80045

303.724.1055 [Phone]
303.724.0990 [Fax]
[COMIRB Home Page](#) [Web]
comirb@ucdenver.edu [E-Mail]
FWA00005070 [FWA]

University of Colorado Hospital
Denver Health Medical Center
Veteran's Administration Medical Center
Children's Hospital Colorado
University of Colorado Denver
Colorado Prevention Center

Certificate of Approval

16-May-2016

Investigator: Dana Dabelea
Subject: COMIRB Protocol 01-934 Continuing Review
Review Date: 10-May-2016
Effective Date: 10-May-2016
Expiration Date: 09-May-2017
Sponsor(s): National Institutes of Health~Juvenile Diabetes Foundation~Centers for Disease Control and Prevention/DHHS~
Title: SEARCH FOR DIABETES IN YOUTH
Expedited Category: 9

Submission ID: CRV015-1

SUBMISSION DESCRIPTION:

Status: Enrollment continues

Your COMIRB Continuing Review submission CRV015-1 has been APPROVED until the expiration date listed above. The investigator will need to submit this research for Continuing Review at least 45 days prior to the expiration date.

Study personnel are approved to conduct the research as described in the documents approved by COMIRB, which are listed below the REVIEW DETAILS section.

Please carefully review the REVIEW DETAILS section because COMIRB may have made red-line changes (i.e. revisions) to the submitted documents prior to approving them. The investigator can submit an amendment to revise the documents if the investigator does not agree with the red-line changes. The REVIEW DETAILS section may also include important information from the reviewer(s) and COMIRB staff.

COMIRB stamps the approved versions of documents in the top right hand corner. Stamped copies of documents are available for download through COMIRB's electronic submission website, eRA(InfoEd).

[Click here for instructions on how to retrieve stamped documents.](#)

REVIEW DETAILS:

CRV015-1

The following documents have been reviewed and stamped APPROVED or NOTED as part of this approval:

Continuing review form (CRV015)

Application for protocol review with attachments A, F, H, M, O, P, Q, R, S; v4.27.16

Cohort Assent form; v4, date 1.29.16

Cohort Consent and authorization form; v4, date 4.15.16

Personnel form; updated 4.15.14

Registry Assent form; version 4, date 1.29.16

Registry Consent and authorization form; v4, date 4.15.16

Response Cover letter; dated 4.27.16

Cohort Grant; no version date

SEARCH protocol; version 2, dated 2.11.16

Registry Grant; no version date

Cohort Spanish Assent form; version 1.3, date 3.4.14

Cohort Spanish Consent and authorization form; version 1.3, date 3.4.14

Registry Assent form; v1.4, date 3.4.14

Registry Spanish Consent and authorization form; v1.4, date 4.3.14

Publications:

Yi-Frazier, J., Hilliard, M., Fino, N., Naughton, M., Liese, A., ...Lawrence, J. (2015, October 14). Whose quality of life is it anyway? Discrepancies between youth and parent health-related quality of life rating in type I and type 2 diabetes. doi 10.1007/s11136-0151158-5.

Shah, A., Dabelea, D., Stafford, J., D'Agostino, R., Mayer-Davis, E., ...Maahs, D. (2015). Change in adiposity minimally affects the lipid profile in youth with recent onset type I diabetes. *Pediatric Diabetes*, 16:280-286. doi 10.1111/pedi.12162.

Chao, L., Beech, B., Crume, T., D'agostino, R., Dabelea, D.,...Merchant, A. (2015). Longitudinal association between television watching and computer use and risk markers in diabetes in the Search for Diabetes in Youth Study, 16; 382-291. doi: 10.1111/pedi.12163.

Law, J., Stafford, J., D'Agostino, R., Badaru, A., Crume, T.,...Mayer-Davis, E. (2015). Association of parental history of diabetes with cardiovascular disease risk factor in children with type 2 diabetes. *Journal of Diabetes and Its Complications*, 29; 534-539. <http://dx.doi.org/10.1016/j.jdiacomp.2015.02.001>.

Abstracts:

Lawrence, J., Hilliard, M., Fino, N., Lang, W., Bell, R., ...Yi-Frazier, J. (2015) Preparation for Transfer from Pediatric to Adult Care among Adolescents with Type I Diabetes. *Diabetes*, 64(suppl. 1): A227.

Snyder, L., Stafford, J., Dabelea, D., Divers, J., Imperatore, G. (2015) SEARCH for Diabetes in Youth Study Group. Socioeconomic, Demographic and Clinical correlates of Poor Glycemic control within Insulin Regimens among Youth with diabetes, 64(suppl. 1): A670.

If this protocol requires full-board review and includes attachment C and/or D, the PI will be required to complete GCP training. COMIRB will begin enforcing this new requirement on 9/1/15. It is highly recommended that you complete this

training as soon as possible to prevent delays on approvals after the 9/1/15 deadline.

For the duration of this research the investigator must:

- Submit any change in the research design, personnel, and any new or changed study documents (including new/changed consent forms, questionnaires, advertisements, ect.) to COMIRB and receive approval before implementing the changes.
- Use only a copy of the COMIRB-approved, stamped Consent and/or Assent Form. The investigator bears the responsibility for obtaining from all subjects "Informed Consent" as required by COMIRB. COMIRB REQUIRES that the subject be given a copy of the consent and/or assent form after it is signed.
- Provide non-English speaking subjects with a certified translation of the approved Consent and/or Assent Form in the subject's first language or use a Consent Short Form, as approved for the study.
- Inform COMIRB immediately of any Unanticipated Problems that are unexpected and related to the study in accordance with COMIRB Policies and Procedures.
- Maintain approval for the research. COMIRB approval is generally given in one year increments, but the period may be shorter. Research is required to be submitted for continuing review and re-approval at least 45 days prior to the expiration date. If a study's approval expires, investigators must stop all research activities immediately (including data analysis) and contact the COMIRB office for guidance.
- Remain actively engaged in the conduct of the research. The investigator must ensure that all enrolled participants are appropriate for the study prior to study procedures beginning. For FDA-regulated research the investigator must sign the investigator line on the consent form prior to participants receiving study-related interventions.

Information on how to submit changes (amendments) to your study, requests for continuing review, and reports of unanticipated problems to COMIRB can be found on the COMIRB website <http://www.ucdenver.edu/COMIRB>.

Contact COMIRB with questions at 303-724-1055 or COMIRB@ucdenver.edu.

As part of this review it was determined that for this research:

1. Risks to subjects are minimized.
2. Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result.
3. Selection of subjects is equitable.
4. Informed consent will be sought from each prospective subject or the subject's legally authorized representative in accordance with, and to the extent required by, §46.116.
5. Informed consent will be appropriately documented in accordance with, and to the extent required by, §46.117.
6. The research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.
7. There are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.
8. Appropriate safeguards are in place to protect potentially vulnerable populations from coercion and undue influence.

Sincerely,

UCD Panel C



THE NAVAJO NATION

RUSSELL BEGAYE PRESIDENT
JONATHAN NEZ VICE PRESIDENT

January 20, 2017

Dr. Dana Dabelea, M.D.
Colorado School of Public Health
Department of Epidemiology
13001 East 17th Place, Bldg. 500, Box B-119
Aurora, Colorado 80045

Dear Dr. Dabelea,

This is to advise you that the **Study #NNR-02.106: "SEARCH for Diabetes in Youth Study"** has been presented to the Navajo Nation Human Research Review Board (NNHRRB) on **January 17, 2017**, and the following action taken subject to the conditions and explanation provided below.

1. Reasons: Quarterly Report
Description: Request Review and Acceptance of Quarterly Report covering October – December 2016 Period.
NNHRRB Action: **Accepted and Approved**
2. Reasons: Annual Report
Description: Request Acceptance and Approval of Annual Report covering January 19, 2016 – January 19, 2017 period.
NNHRRB Action: **Accepted and Approved**
Conditions: All Standard Conditions
3. Reasons: Approval for Dissemination
Description: Request Review and Approval to Disseminate Fact Sheet and Newsletter, and Approval of Abstract to be used in Conference Presentation in July 2017 if abstract is selected.
NNHRRB Action: **Accepted and Approved**
Conditions: All Standard Conditions
4. Reasons: Continuation Request
Description: Request Acceptance and Approval of Continuation Request covering January 19, 2017 – January 19, 2018 period.
NNHRRB Action: **Accepted and Approved**
Conditions: All Standard Conditions

The Navajo Nation Human Research Review Board has added a very important additional contingency regarding failure to comply with NNHRRB rules, regulations, and submittal of reports which could result in sanctions being placed against your project. This could also affect your funding source and the principal investigator. Under Part Five: Certification, please note paragraph five wherein it states: *"I agree not to proceed in the research until the problems have been resolved or the Navajo Nation Human Research Review Board has reviewed and approved the changes."* Therefore, it is very important to submit quarterly and annual reports on time and if continuation is warranted submit a letter of request sixty (60) days prior to the expiration date.

The following are requirements that apply to all research studies:

1. The Navajo Nation retains ownership of all data obtained within its territorial boundaries. The Principal Investigator shall submit to the NNHRRB a plan and timeline on how and when the data/statistics will be turned over to the Navajo Nation;
2. Only the approved informed consent document(s) will be used in the study;
3. Any proposed future changes to the protocol or the consent form(s) must again be submitted to the Board for review and approval prior to implementation of the proposed change;
4. If the results of the study will be published or used for oral presentations at professional conferences, the proposed publication, abstract and/or presentation materials must be submitted to the Navajo Research Program for Board review and prior approval;

5. Upon Board approval, three (3) copies of the final publication must be submitted to the Navajo Research Program;
6. All manuscripts must be submitted to the Navajo Research Program for Board Review and prior approval;
7. The Principal Investigator must submit a dissemination plan on how the results of the study and how these results will be reported back to the Navajo Nation;
8. The Principal Investigator must share specifically how these results will generally benefit or improve the health of the Navajo people. This can be completed by:
 - a. Conducting an educational in-service for the community people and health care providers on the Navajo Nation and present the findings. Provide documentation of these in-services presented.
 - b. Developing educational materials for use by the health care providers and the community people and providing the training on how to use the materials; and
 - c. Presenting and sharing the results of the study at a research conference sponsored by the Navajo Nation for its health care providers and the Navajo people.
9. The Principal Investigator is expected to submit documentation on 8a, b, & c;
10. The Principal Investigator must submit quarterly and annual reports as scheduled.

If you have any other questions on this subject, please call the Navajo Research Program at (928) 871-6929.

Sincerely Yours,



Beverly Becenti-Pigman, Chairperson
Navajo Nation Human Research Review Board

cc: #NNR-02.106 file

Institutional Review Board
Kaiser Permanente Southern California

June 08, 2016

KPSC Principal Investigator(s)

Dr. Jean M Lawrence, ScD, KPSC - Research & Evaluation
100 S. Los Robles Avenue,
Pasadena, CA 91188

KPSC Co-Investigator(s)

Kristi Reynolds, PhD Mary Helen Black, PhD

Study Title: SEARCH for Diabetes in Youth, Phase 3: California Center (#5836)

At its May 17, 2016 meeting, the IRB voted to approve the protocol modification with the following condition:

- Limit the number of attempted contacts to a total 4 per subject so that subject's decisions to participate are made voluntarily in line with the Belmont Report principle of respect. The IRB determined that an attempted contact is when information is passed to a human subject by the study team in any format such as letter, email, text, voicemail and a phone call in which the respondent or a member of the household responds verbally.

On June 1, 2016, the IRB reviewed and accepted the PI response confirming to limit the number of attempted contacts to no more than 4.

No further IRB action is required.

Below is a summary of the documents fully approved as part of this modification submission.

Title	Version Date
Modifications spreadsheet for Cohort and Registry study	04/07/2016
SEARCH 4 cohort survey Parent 14 - 17 04-01-2016	04/01/2016
SEARCH 4 cohort survey Parent 10 - 13 04-01-2016	04/01/2016
SEARCH 4 cohort survey Young Adult 18 - 25 04-01-2016	04/01/2016
SEARCH 4 cohort survey Teen 14 - 17 04-01-2016	04/01/2016
SEARCH 4 cohort survey Adult 26+ 04-01-2016	04/01/2016
SEARCH 4 cohort survey Child 10 - 13 04-01-2016	04/01/2016

Certificate of Confidentiality DK-16-014	03/25/2016
Cohort Contact Email Script (Parent)	03/28/2016
Cohort Contact Email Script (Young adult)	03/28/2016
Cohort visit invitation letter for participants 18 and older	03/28/2016
Cohort visit invitation letter for Parents	03/28/2016
SEARCH 4 Protocol Version 2 Feb 11 2016	02/11/2016

The IRB approved the revisions to the 1) Registry and Cohort ICF 18+ and 2) Registry and Cohort Parent Guardian informed consent form(s)

The informed consent form(s) including the HIPAA Authorization section have been finalized and posted in the iRIS consent form history queue. If you have any questions or need any information regarding the consent form(s), please contact Daria Diaz at (626) 405-5972 (tie line 8/335-5972).

Sincerely,

Signature applied by Daria Diaz on 06/08/2016
10:14:47 AM PDT

Armida Ayala, MHA, PhD
Director
Human Research Subjects Protection Office
Institutional Review Board



APPROVAL OF SUBMISSION

June 3, 2016

[Catherine Pihoker](#)

catherine.pihoker@seattlechildrens.org

Dear Dr. [Catherine Pihoker](#):

On 6/3/2016, the IRB reviewed the following submission:

Type of Review:	Continuing Review
Title of Study:	SEARCH for Diabetes in Youth 4
Investigator:	Catherine Pihoker
Activity ID:	CR00000357
IRB ID:	PIROSTUDY12074
Funding:	Name: Centers for Disease Control and Prevention, Funding Source ID: U18DP006136; Name: National Institute of Diabetes and Digestive and Kidney Diseases, Funding Source ID: 1UC4DK108173
Grant ID:	None
IND, IDE, or HDE:	None
Documents Reviewed:	<ul style="list-style-type: none"> • IPS Information Sheet , Category: Consent Form; • Registry visit consent, clean, Category: Consent Form; • Cohort Survey Cover Letter , Category: Consent Form; • Cohort visit consent, clean , Category: Consent Form;

The IRB approved the Continuing Review from 6/3/2016 to 6/2/2017 inclusive. At least 45 calendar days prior to approval expiration, you are to submit a continuing review with required explanations. You can submit a continuing review by navigating to the active study and clicking Create Modification / CR.

If continuing review approval is not granted before the expiration date of 6/2/2017, approval of this study expires on that date.

In conducting this study, you are required to follow the requirements listed in the Investigator Manual (HRP-103), which can be found by navigating to the IRB Library within the IRB system.

Sincerely,
[Rosemay Vazeux](#), MD, CIP, IRB Vice Chair

Office of Research
INSTITUTIONAL REVIEW BOARD.

MEMORANDUM

To: Ralph DAgostino Jr, Ph.D.
Biostatistical Sciences Facult

From: Chair,
Institutional Review Board

Date: 10/24/2016

Subject: Human Protocol: IRB00015926
SEARCH for Diabetes in Youth - Phase 3 - Coordinating Center

Study Documents:

Protocol Version: 2015_10_30_SEARCH 4 Protocol_Clean.pdf, 2016_02_11_SEARCH 4 Protocol Version 2 CLEAN.pdf, SEARCH_AIR_protocol_jul2012_changeshighlighted.pdf, SEARCH 3 Protocol 8-2011, SEARCH AIR_UMD_Amendment Approval_7_2012.pdf, SEARCH AIR ANCILLARY STUDY PROTOCOL_11_2011, SEARCH AIR UMD IRB Approval Memo_9_2011, SEARCH EYE_Kidney Ancillary Study Protocol.pdf, SEARCH_Harmonization of existing registries of diabetes in youth_Ancillary Study Protocol_7_11_2016.pdf, SEARCH_AIR_Amendment Application_UMD_7_2012.pdf, SEARCH_Role of epigenetics factors in beta-cell dysfunction in youth with T1D (Pilot Study)_Ancillary Study Protocol_9_13_2016.pdf; Informed Consent Version: 2015_10_30_SEARCH 4 Cohort Visit Model Consent Template_Clean.docx (approved), 2015_10_30_SEARCH 4 Registry Visit Model Consent Template_Clean.docx (approved), Cohort Consent Template (approved), Registry Consent Template (approved); Assent Version: 2015_10_30_SEARCH 4 Cohort Visit Model Assent Template_Clean.docx (approved), 2015_10_30_SEARCH 4 Registry Visit Model Assent Template_Clean.docx (approved); Other Documents: BROAD_ILLUMINA_SEARCH_MOU_signed.pdf, Cohort Study Recruitment Brochure (Washington site), Contact Information - Participant, Contact Information Form - Parent version, Diabetes Eating Problem Survey - age 10 and older, Diabetes Related Family Conflict Survey - Parent version, Diabetes Related Family Conflict Survey - Participant age 10 and older, Extended Core Information form revised 11-07-11, Family Medical History form, Food Frequency Questionnaire revised 10-05-11, Health Questionnaire - Parent version, Health Questionnaire - Participant version, Initial Participant Survey - Parent version revised 11-08-11, Initial Participant Survey - Participant version revised 11-08-11, Kaiser Permanente IRB Approval Letter, Low Blood Sugar Survey - Adult age 18 and over, Low Blood Sugar Survey - Child Teen age 10-17 version, Low Blood Sugar Survey - Parent revised 10-26-11, Medical Record Validation of Self-Report, Medication Inventory form, Neuropathy form, Participating Relatives form, Pediatric Diabetes Quality of Life - Parent version, Pediatric Quality of Life - Participant version, PedsQL Child Report (ages 5-7), PedsQL Child Report (ages 5-7) Diabetes module, PedsQL Child Report (ages 8-12), PedsQL Child Report (ages 8-12) Diabetes module, PedsQL Parent Report for Children (ages 8-12), PedsQL Parent Report for Children (ages 8-12) Diabetes module, PedsQL Parent Report for Teens (ages 13-18), PedsQL Parent Report for Teens (ages 13-18) Diabetes module, PedsQL Parent Report for Toddlers (ages 2-4), PedsQL Parent Report for Toddlers (ages 2-4) Diabetes module, PedsQL Parent Report for Young Children (ages 5-7), PedsQL Parent Report for Young Children (ages 5-7) Diabetes module, PedsQL Teen Report (ages 13-18), PedsQL Teen Report (ages 13-18) Diabetes module, PedsQL Young Adult (ages 19 and over), PedsQL Young Adult (ages 19 and over) Diabetes module, Physical Exam Cohort 11-01-10, Physical Exam Registry 11-01-10, Quality of Care - Parent version revised 10-26-11, Quality of Care - Participant version revised

10-26-11, Rationale and Plan for the SEARCH Central Web-Based Tracking Database and Data Management System, Registry Study Recruitment Brochure (Washington site), SEARCH 4 Cohort All Sites IRB Approved Consent Assent.pdf, SEARCH 4 REGISTRY All Sites IRB Approved Consent Assent.pdf, SEARCH AIR_UMD RIB approval _9_2011, SEARCH DATA SECURITY DOCUMENT_6_24_2015, SEARCH Exemption-Request__Vanderbilt.pdf, SEARCH Phase 3 Protocol Section 5A_Case Ascertainment & Data Collection_Registry CLEAN 083111.pdf, SEARCH Phase 3 Protocol Section 5B_Data Collection_Cohort CLEAN 083111.pdf, SEARCH_AIR_Ancillary Study Protocol _11_2011, SEARCH_GWAS_dbGaP_Certification Approval Memos_Combined_7_2014.pdf, SEARCH-T2D GENES Study Agreement, Specimen Collection form revised 10-14-11, SphygmoCor form, Supplemental Questionnaire for age 10 and older, Tanner Stage - Female, Tanner Stage - Male, Unanticipated Occurrence Condition Reporting form, Unregistration form, Vanderbilt IRB Approval Memo_Lucy_D'Agostino_Mcgowan.pdf

This is to confirm for your record that the Institutional Review Board reviewed your progress report and consent form, containing compounded HIPAA authorization language, if applicable, for the above-named protocol. IRB approval was activated on 10/24/2016 and will expire on 10/23/2017. If the protocol is to remain active longer, a written request for renewal, together with a summary progress report, and a copy of the current consent form, if applicable, should be submitted to the Board at least one month prior to expiration.

This research meets the criteria for a waiver of consent entirely according to 45 CFR 46(d).

This research meets the criteria for a waiver of assent according to 45 CFR 46.116(d).


This research meets the criteria for a waiver of HIPAA authorization according to 45 CFR 164.512.

Based on the information provided, the IRB has determined that HIPAA does not apply to this study.

This research, which involves children, meets the criteria at 45 CFR 46.404 (research involving no greater than minimal risk). Permission of one parent or guardian is sufficient.

Please provide a final report to the Board when the project is completed and Board approval can be terminated.

This IRB is in compliance with the requirements in Part 56, Subchapter D, Part 312 of the 21 Code of Federal Regulations published January 27, 1981 and Part 46, Subpart A of 45 CFR published January 26, 1981.



Gregory Kucera, Ph.D.